No Data
Wells Fargo Adjusts Price Target on Johnson & Johnson to $170 From $152, Keeps Equalweight Rating
Johnson & Johnson Announces TREMFYA Is The First And Only IL-23 Inhibitor To Reduce Both The Signs And Symptoms And The Progression Of Structural Damage In Adults Living With Active Psoriatic Arthritis
Express News | Johnson & Johnson - Tremfya Shows Less Structural Damage Progression at Week 24
Express News | Johnson & Johnson - Tremfya Safety Profile Consistent With No New Safety Signals
Express News | Johnson & Johnson - Tremfya Phase 3B Study Achieves Primary and Secondary Endpoints
Express News | Tremfya® (Guselkumab) Is the First and Only Il-23 Inhibitor to Significantly Reduce Both the Signs and Symptoms and the Progression of Structural Damage in Adults Living With Active Psoriatic Arthritis
